Targeting inflammation: multiple innovative ways to reduce prostaglandin E2-Reference-Cited by-同舟云学术

Targeting inflammation: multiple innovative ways to reduce prostaglandin E2

Published:2013-03 Issue:2 Volume:2 Page:265-288
ISSN:2046-8954
Container-title:Pharmaceutical Patent Analyst
language:en
Short-container-title:Pharmaceutical Patent Analyst

Author:

Norberg Jessica K¹,Sells Earlphia¹²,Chang Hui-Hua¹³,Alla Srinivas R⁴,Zhang Shuxing⁴,Meuillet Emmanuelle J²³⁵

Affiliation:

1. The University of Arizona Cancer Center, Tucson, AZ 85724, USA

2. Molecular & Cellular Biology Department, University of Arizona, Tucson, AZ 85721, USA

3. Nutritional Sciences Department, University of Arizona, Tucson, AZ 85721, USA

4. Experimental Therapeutics Department, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA

5. The University of Arizona Cancer Center, Tucson, AZ 85724, USA.

Abstract

The PGE2 pathway is important in inflammation-driven diseases and specific targeting of the inducible mPGES-1 is warranted due to the cardiovascular problems associated with the long-term use of COX-2 inhibitors. This review focuses on patents issued on methods of measuring mPGES-1 activity, on drugs targeting mPGES-1 and on other modulators of free extracellular PGE2 concentration. Perspectives and conclusions regarding the status of these drugs are also presented. Importantly, no selective inhibitors targeting mPGES-1 have been identified and, despite the high number of published patents, none of these drugs have yet made it to clinical trials.

Publisher

Future Science Ltd

Subject

General Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/ppa.12.90

Reference181 articles.

1. Inflammation as a tumor promoter in cancer induction

2. The production of prostanoids in human cancers, and their implications for tumor progression

3. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion)

4. Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrazoles have a multifaceted anti-inflammatory effect targeting prostaglandin E2, cyclooxygenases and leukocytes’ oxidative burst;The International Journal of Biochemistry & Cell Biology;2024-07

2. In Silico Exploration of Molecular Mechanisms for Inhibiting Inflammatory Responses by 3Н-Thiazolo[4,5-b]pyridin-2-one Derivatives;Acta Chimica Slovenica;2024-06-20

3. Sargachromenol Attenuates Inflammatory Responses by Regulating NF-κB and Nrf2 Pathways in RAW 264.7 Cells and LPS-treated Mice;Planta Medica;2023-10-17

4. Sargahydroquinoic Acid, a Cyclooxygenase-2 Inhibitor, Attenuates Inflammatory Responses by Regulating NF-κB Inactivation and Nrf2 Activation in Lipopolysaccharide-Stimulated Cells;Inflammation;2021-05-29

5. Lipopolysaccharide stimulates bovine endometrium explants through toll‑like receptor 4 signaling and PGE2 synthesis;Prostaglandins, Leukotrienes and Essential Fatty Acids;2021-05